Figure 1.

Overview of the virtual molecular tumor board workflow. Patients referred to Perthera’s virtual molecular tumor board (VMTB) for personalized treatment recommendations are consented to an IRB-approved registry. After obtaining medical records and facilitating the successful completion of molecular testing by commercial laboratories, structured data, and unstructured documents are integrated into a HIPAA-compliant cloud-based knowledgebase. A preliminary report is produced through our comprehensive, rules-based data engine which produces the initial ranked therapies. VMTB users are invited to review individual cases in a secure online portal that features an asynchronous chat window and the ability to formulate, modify, and rank personalized recommendations. After discussions are closed, a final report consisting of ranked therapy options consisting of on-label, off-label, and experimental interventions are delivered to patients and their treating oncologists. Workflow enhancements include automated treatment matching algorithms that provide a preliminary set of therapy options with clinical trial recommendations for VMTB users to discuss and modify. This iteratively improved platform aims to provide a patient-centered platform for scalable precision oncology that leverages real-world outcomes (additional consent provided for post-report records collection), curated literature evidence and domain-specific clinical expertise.